Seizure drug may shield the brain after cardiac arrest — a trial puts it to the test

NCT ID NCT06401707

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

After a cardiac arrest, many survivors develop seizures that can worsen brain injury. This trial tests whether giving the drug perampanel soon after resuscitation can prevent those seizures. About 52 adults who are comatose after a cardiac arrest will receive either perampanel or a placebo for five days. The study will check if the drug is safe and feasible to use in this setting, and whether it reduces the number of seizures.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
perampanel (also known as Fycompa), a drug that blocks AMPA glutamate receptors in the brain
What this could lead to
If it works, this could point toward a way to prevent brain-damaging seizures after cardiac arrest, potentially improving survival and recovery.
What could go wrong
This is a small early-stage trial focused on safety and feasibility, so it is too soon to know if perampanel truly prevents seizures or improves outcomes. The drug may also cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART ARREST are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Zuckerberg San Francisco General Hospital

    RECRUITING

    San Francisco, California, 94110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.